CN114042161B - Application of CENPW inhibitor in preparation of antitumor drugs - Google Patents

Application of CENPW inhibitor in preparation of antitumor drugs Download PDF

Info

Publication number
CN114042161B
CN114042161B CN202111360914.5A CN202111360914A CN114042161B CN 114042161 B CN114042161 B CN 114042161B CN 202111360914 A CN202111360914 A CN 202111360914A CN 114042161 B CN114042161 B CN 114042161B
Authority
CN
China
Prior art keywords
cenpw
breast cancer
sequence
gene
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111360914.5A
Other languages
Chinese (zh)
Other versions
CN114042161A (en
Inventor
王莹
杜璟
王陆洋
李艳纯
童向民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Provincial Peoples Hospital
Original Assignee
Zhejiang Provincial Peoples Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Provincial Peoples Hospital filed Critical Zhejiang Provincial Peoples Hospital
Priority to CN202111360914.5A priority Critical patent/CN114042161B/en
Publication of CN114042161A publication Critical patent/CN114042161A/en
Application granted granted Critical
Publication of CN114042161B publication Critical patent/CN114042161B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention relates to a CENPW inhibitor and application thereof in preparing antitumor drugs, wherein the CENPW inhibitor is a CENPW-i-1siRNA sequence and a CENPW-i-2siRNA sequence for reducing CENPW nucleic acid or protein expression, and the CENPW-i-1siRNA sequence and the CENPW-i-2siRNA sequence have at least 90% sequence homology with SEQ ID NO. 1 and SEQ ID NO. 2 respectively. The invention discovers that substances for reducing CENPW expression interfere proliferation and migration of human breast cancer cells, thereby playing an anticancer role and providing a direction for research and development of antitumor drugs.

Description

Application of CENPW inhibitor in preparation of antitumor drugs
Technical Field
The invention relates to the field of biology, in particular to application of a CENPW gene inhibitor.
Background
According to the latest global cancer burden data in 2020 issued by IARC, the new incidence rate of the global breast cancer is up to 47.8%, which accounts for nearly half of the incidence rate of the global cancer. Breast cancer is the cancer with the leading incidence of female malignancy, and its exact carcinogenic mechanism is under study. The treatment of breast cancer at the present stage is mainly drug chemotherapy and surgical treatment. Surgical removal of tumors remains the treatment of choice for breast cancer patients, with improved radical surgery being the current procedure, but the choice of procedure should be based on a combination of breast cancer stage and patient physical condition. The main chemotherapeutics for treating breast cancer are anthracyclines and taxoids. However, chemotherapeutic drugs are prone to adverse effects on other organs of the body, causing various discomforts. Obvious drug resistance can be generated after long-term use of chemotherapeutic drugs. The relative survival rate of breast cancer patients for 5 years is 89.9%, wherein the survival rate of in-situ cancer for 5 years is 98.8%, the survival rate of early invasive cancer for 5 years is 85.5%, and the survival rate of invasive cancer for 5 years with distant metastasis is only 27.4%. It can be seen that early screening of breast cancer helps to increase early detection rate, and has an important role in reducing morbidity and mortality. Thus, the study of biomarkers to detect early breast cancer is of paramount importance.
From the aspect of gene therapy, exogenous genes designed and modified are transfected into breast cancer cells, so that proliferation and migration capacity of the cells are disturbed and inhibited. Through extensive bioinformatics data analysis, the CENPW gene was found to be a predictor of breast cancer. The centromere protein W (CENP-W) encoded by the CENPW gene is an important member of the constitutive centromere related network (CCAN) family, playing a vital role in nucleosome assembly. The full-length mRNA of the CENPW gene is about 600bp in size and is located on human chromosome 6q22.32, and its regulatory region is located upstream of the TSS region. Through continuous researches, the formation of tumors is a process of mutually regulating and controlling multiple genes, and the molecular pathology mechanism research of breast cancer is gradually changed from the research of a chemotherapy drug mechanism to the research direction of regulating and controlling multiple gene signal channels.
Disclosure of Invention
The invention aims to overcome the defects in the prior art and provide a CENPW gene inhibitor and application thereof in preparing antitumor drugs.
Through extensive bioinformatics data analysis, the inventor finds that the mRNA specific expression of CENPW gene is obviously higher than that of paracancestral tissue cells in breast cancer cells, the expression quantity is closely related to pathological stage, and the expression quantity of stage IV is obviously higher than that of stage III, stage II and stage I. The CENPW gene plays an important role in the growth cycle process of breast cancer cells, and the proliferation capacity and migration capacity of a breast cancer cell line BT-549 can be obviously inhibited by interfering or inhibiting the expression of the CENPW gene by siRNA, so that the growth and propagation speed of the breast cancer cells can be effectively controlled. Therefore, the expression of CENPW is knocked down in breast cancer cells BT-549 in a mode of specific siRNA interference, and a good effect of inhibiting cell proliferation can be obtained. These results show that the CENPW gene expression has a close regulation and control effect on the growth of breast cancer cells, and provides a novel thought for treating cancer inhibition targets and drug forms of breast cancer, and also provides novel biomarkers and predictors for detecting early breast cancer. In addition, detection of significantly elevated expression levels of the CENPW gene in clinical breast cancer cell specimens also provides further feasibility and reliability for clinical tumor diagnosis and prognosis.
Based on the above findings, the technical solution for solving the above technical problems provided by the present invention is as follows.
In a first aspect the invention provides an anti-tumour agent comprising a CENPW gene inhibitor.
In a second aspect, the invention provides the use of a CENPW gene assay for the preparation of a reagent for diagnosing a neoplastic disease in a patient or for determining the prognostic level of a tumour in a patient.
Preferably, the diagnostic neoplastic disease is a breast cancer disease; more preferably, it is a breast cancer disease in stage IV.
The third aspect of the invention provides an application of CENPW gene inhibitor in preparing anti-tumor drugs.
Preferably, the CENPW gene inhibitor is a compound that reduces expression of a CENPW gene nucleic acid or protein.
More preferably, the CENPW gene inhibitor is a CENPW-i-1 or CENPW-i-2 nucleic acid sequence, the CENPW-i-1 is a CENPW-i-1siRNA sequence directed against the CENPW nucleic acid sequence, the nucleotide sequence of which has at least 90% sequence homology with SEQ ID NO. 1; the CENPW-i-2 is a CENPW-i-2siRNA sequence aiming at the CENPW nucleic acid sequence, and the nucleotide sequence of the CENPW-i-2siRNA sequence has at least 90% of sequence homology with SEQ ID NO. 2.
More preferably, the CENPW-i-1siRNA sequence has at least 95% sequence homology, or at least 98% sequence homology, or at least 99% sequence homology with SEQ ID NO. 1.
More preferably, the CENPW-i-2siRNA sequence has at least 95% sequence homology, or at least 98% sequence homology, or at least 99% sequence homology with SEQ ID NO. 2.
Most preferably, the CENPW-i-1siRNA sequence is shown in SEQ ID NO. 1.
The nucleotide sequence of SEQ ID NO. 1 is as follows:
5’-GCAGAAGAGTCCAGGACAA-3’。
most preferably, the CENPW-i-2siRNA sequence is shown in SEQ ID NO. 2.
The nucleotide sequence of SEQ ID NO. 2 is as follows:
5’-GGAGAAAAGTGGTGACTTA-3’。
preferably, the tumor is a breast cancer cell tumor.
More preferably, the breast cancer cell tumor is a breast cancer cell line BT-549.
The invention has the beneficial effects that:
the invention surprisingly finds that the CENPW gene expression level is obviously higher than that of a tissue beside a cancer, the protein expression level is obviously increased in breast cancer cells of a patient, and the CENPW gene expression level plays an important role in proliferation and migration of breast cancer. The siRNA interfering CENPW gene is developed to transfect breast cancer cells, so that the expression level of the CENPW gene is knocked down, a certain anticancer effect is achieved, and the treatment of interfering tumor proliferation and metastasis is facilitated. In view of the fact that the CENPW gene can be used as a predictive factor of novel cancers, the CENPW gene inhibitor opens up a new idea for developing anti-breast cancer drugs.
Drawings
FIG. 1 is a statistical graph of the expression level of CENPW gene in primary tumor (human breast cancer tissue) and normal tissue (paracancerous tissue) based on TCGA database.
FIG. 2 is a statistical chart of the expression level of CENPW gene in tumor stage (I-IV stage) of human breast cancer tissue based on TCGA database.
FIG. 3 is a graph showing the effect of CENPW-i-1 and CENPW-i-2 on the expression of CENPW protein, wherein FIG. 3A is a graph showing the blotting result of CENPW-i-1 and CENPW-i-2 on CENPW protein, and FIG. 3B is a statistical graph showing the decrease of CENPW protein expression by CENPW-i-1 and CENPW-i-2.
FIG. 4 is a graph showing the results of CENPW gene inhibitor in inhibiting cell proliferation of human breast cancer cell BT-549, wherein FIG. 4A is a graph showing the results of CCK-8 assay growth curve, FIG. 4B is a graph showing the results of plate cloning experiment, and FIG. 4C is a statistical graph of plate cloning experiment.
FIG. 5 is a graph showing the results of a CENPW gene inhibitor migration transwell test for BT-549 cells (CENPW-i-1 group represents siRNA-1 interfering with CENPW expression, CENPW-i-2 group represents siRNA-2 interfering with CENPW expression), and FIG. 5B is a graph showing the statistics of the test.
FIG. 6 is a graph of the results of a CENPW gene inhibitor in inhibiting the migration scratch of BT-549 cells, wherein FIG. 6A is a graph of the results of the experiment (CENPW-i-1 is siRNA-1 interfering with CENPW expression, CENPW-i-2 is siRNA-2 interfering with CENPW expression), and FIG. 6B is a graph of experimental statistics.
Detailed Description
The present invention will be described in further detail with reference to examples and drawings, but embodiments of the present invention are not limited thereto.
EXAMPLE 1 mining CENPW Gene expression levels in breast cancer data based on TCGA tumor database
To search for the possibility and importance of CENPW inhibitors in clinical applications, mRNA expression levels of CENPW in breast cancer were first analyzed using TCGA tumor database. The data shows that CENPW was significantly higher in breast cancer than in normal tissues (fig. 1).
Analysis of CENPW expression levels in human breast cancer tissue tumor stage based on TCGA database revealed that the expression levels were related to pathological stage, and that the expression levels in stage IV were higher than those in stage III, stage II and stage I (fig. 2).
The TCGA tumor database analysis proves that the expression of CENPW in cancer tissues is obviously higher than that of other tissues, and the expression level of CENPW is closely related to pathological stage of tumor, which indicates that the expression of CENPW gene is a novel marker for clinical breast cancer diagnosis.
Example 2 influence of CENPW on proliferation and migration Capacity of human breast cancer cell line BT-549
The human breast cancer cell line BT-549 was selected to investigate the effect of CENPW on breast cancer cell proliferation and migration. A negative control vector with NO homology between CENPW-i-1 and CENPW-i-2 (SEQ ID NO:1 and SEQ ID NO: 2) and control siRNA (si-NC) is constructed, wherein the negative control vector is 5'-CAGTCGCGTTTGCGACTGG-3', and the negative control vector is a disordered nucleotide sequence of a non-targeted whole genome nucleic acid sequence, and is verified by large-scale data analysis and experiments, and does not target any known human, mouse and rat genes. And determining the nucleotide sequence, and obtaining an siRNA finished product by using an siRNA synthesis technology of Guangzhou Ruibo biotechnology Co.
Human breast cancer cell line BT-549 was cultured, plated in 6-well plates (30 ten thousand cells/well), when the cell density of the human breast cancer cell line BT-549 was 50%, the above CENPW-i-1 and CENPW-i-2 and control siRNA were mixed using a liposome transfection method, specifically, 5. Mu.l of 20nm siRNA plasmid and 5. Mu.l of liposome (lipofectamine 3000, invitrogen Co.) and then added to the cell plates of the 6-well plates, and after 12 hours, fresh culture medium was changed. And (5) after 48 hours of transfection, checking the interference effect.
Western blot results showed that the CENPW expression level in BT-549 cell lines could be reduced by about 40% by the interference of CENPW-i-1 and CENPW-i-2 compared to si-NC control (fig. 3A and 3B).
Cells transfected with si-NC, CENPW-i-1 and CENPW-i-2 were inoculated into 96-well plates (5000 cells/well) and cultured under the same conditions, and were examined for CCK-8 proliferation at 0, 1, 2, and 3 days, respectively. This cell model demonstrated that interfering with CENPW expression with siRNA can effectively inhibit proliferation of breast cancer cells (fig. 4A). And respectively taking 500 transfected BT-549 cells, culturing in a six-hole plate under the same condition for 14 days, and carrying out a plate cloning experiment to observe the proliferation condition of the cells. This cell model was also a demonstration that interfering with CENPW expression with siRNA could effectively inhibit proliferation of breast cancer cells (fig. 4B and 4C).
The invasion experiment was performed using transfected BT-549 cells, 5 ten thousand cells were mixed with 200. Mu.l of serum-free medium and added to the upper chamber of the invasion chamber, which was filled with complete medium with 10% serum. After 24 hours and 48 hours of culture, the cells were fixed and stained, and the migration of the cells was observed under a microscope. This cell migration model also demonstrated that lowering the expression level of CENPW was effective in inhibiting migration of human breast cancer cells (fig. 5A and 5B).
Transfected cells were seeded at the same density in 6-well plates and cultured under the same conditions, and replaced with serum-free medium while performing the streak assay. Cell migration was then observed under a microscope at 0 hours, 24 hours and 48 hours. This cell migration model demonstrated that lowering the expression level of CENPW was effective in inhibiting migration of human breast cancer cells (fig. 6A and 6B).
The test results prove that the CENPW gene is highly expressed in breast cancer cells, and the migration and proliferation capacity of the breast cancer cells BT-549 can be obviously inhibited by knocking down the expression level of the CENPW gene inhibitor. Therefore, the expression condition of CENPW protein can be used as a prediction factor of clinical tumor, and is an important routine index especially for diagnosing breast cancer. By comprehensively considering other indexes and the expression level of CENPW, the tumor diagnosis and the prognosis level of a patient can be further accurately carried out. In addition, the proliferation and migration of human breast cancer cells can be inhibited by reducing CENPW gene expression mode, thereby having the technical effect of inhibiting the development and metastasis of tumor.
Therefore, the invention uses the method of gene regulation to inhibit the expression of CENPW gene at the transcription level, solves the problems of great adverse reaction and drug resistance caused by the existing breast cancer chemotherapeutic drugs, and can achieve better anticancer effect by combining other treatment means.
The invention can also be applied to diagnosis of tumors of other systems and drug development targets. The present invention is intended to be within the scope of protection for diagnosis by detecting the expression of the CENPW gene, and for treatment of tumors by reducing or inhibiting the expression of the CENPW gene.
The above examples are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above examples, and any other changes, modifications, substitutions, combinations, and simplifications that do not depart from the spirit and principle of the present invention should be made in the equivalent manner, and the embodiments are included in the protection scope of the present invention.
Sequence listing
<110> Zhejiang province people Hospital
Application of <120> CENPW inhibitor in preparation of antitumor drugs
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 19
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 1
gcagaagagt ccaggacaa 19
<210> 2
<211> 19
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 2
ggagaaaagt ggtgactta 19

Claims (2)

1. The anti-tumor drug is characterized by comprising a CENPW gene inhibitor, wherein the CENPW gene inhibitor is a CENPW-i-1siRNA sequence or a CENPW-i-2siRNA sequence, the CENPW-i-1siRNA sequence is shown as SEQ ID NO. 1, the CENPW-i-2siRNA sequence is shown as SEQ ID NO. 2, and the tumor is breast cancer cell tumor.
2. The application of the CENPW gene inhibitor in preparing antitumor drugs is characterized in that the CENPW gene inhibitor is a CENPW-i-1siRNA sequence or a CENPW-i-2siRNA sequence, the CENPW-i-1siRNA sequence is shown as SEQ ID NO. 1, the CENPW-i-2siRNA sequence is shown as SEQ ID NO. 2, and the tumor is breast cancer cell tumor.
CN202111360914.5A 2021-11-17 2021-11-17 Application of CENPW inhibitor in preparation of antitumor drugs Active CN114042161B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111360914.5A CN114042161B (en) 2021-11-17 2021-11-17 Application of CENPW inhibitor in preparation of antitumor drugs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111360914.5A CN114042161B (en) 2021-11-17 2021-11-17 Application of CENPW inhibitor in preparation of antitumor drugs

Publications (2)

Publication Number Publication Date
CN114042161A CN114042161A (en) 2022-02-15
CN114042161B true CN114042161B (en) 2023-05-30

Family

ID=80209608

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111360914.5A Active CN114042161B (en) 2021-11-17 2021-11-17 Application of CENPW inhibitor in preparation of antitumor drugs

Country Status (1)

Country Link
CN (1) CN114042161B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3907301A1 (en) * 2020-05-08 2021-11-10 Istituto Europeo di Oncologia S.r.l. Methods and kits for determining the risk of breast cancer recurrence

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111739586B (en) * 2020-06-17 2024-04-05 浙江大学 Model for predicting cell proliferation activity by using 87 genes as biomarkers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3907301A1 (en) * 2020-05-08 2021-11-10 Istituto Europeo di Oncologia S.r.l. Methods and kits for determining the risk of breast cancer recurrence
WO2021224466A1 (en) * 2020-05-08 2021-11-11 Istituto Europeo Di Oncologia S.R.L. Methods and kits for determining the risk of breast cancer recurrence

Also Published As

Publication number Publication date
CN114042161A (en) 2022-02-15

Similar Documents

Publication Publication Date Title
Hu et al. USP22 promotes tumor progression and induces epithelial–mesenchymal transition in lung adenocarcinoma
Wang et al. MicroRNA-373 inhibits cell proliferation and invasion via targeting BRF2 in human non-small cell lung cancer A549 cell line
Li et al. MicroRNA-4472 promotes tumor proliferation and aggressiveness in breast cancer by targeting RGMA and inducing EMT
Zeng et al. lncRNA 00312 attenuates cell proliferation and invasion and promotes apoptosis in renal cell carcinoma via miR-34a-5p/ASS1 axis
Han et al. Low-expression of TMEM100 is associated with poor prognosis in non-small-cell lung cancer
Zhao et al. Long noncoding RNA NSCLCAT1 increases non–small cell lung cancer cell invasion and migration through the Hippo signaling pathway by interacting with CDH1
Tang et al. MiR-876-3p targets KIF20A to block JAK2/STAT3 pathway in glioma
Miyamoto et al. Kinesin family member 14 in human oral cancer: A potential biomarker for tumoral growth
Wang et al. LncRNA-IUR up-regulates PTEN by sponging miR-21 to regulate cancer cell proliferation and apoptosis in esophageal squamous cell carcinoma
Ke et al. MiR-514a-3p inhibits cell proliferation and epithelial-mesenchymal transition by targeting EGFR in clear cell renal cell carcinoma
Rao et al. LncRNA SNHG3 promotes gastric cancer cells proliferation, migration, and invasion by targeting miR-326
Zeng et al. CD82/KAI1 inhibits invasion and metastasis of esophageal squamous cell carcinoma via TGF-β1.
Bi et al. Circ-HIPK3 regulates YAP1 expression by sponging miR-381-3p to promote oral squamous cell carcinoma development
Liang et al. Linc00467 promotes invasion and inhibits apoptosis of head and neck squamous cell carcinoma by regulating miR-1285-3p/TFAP2A
Wang et al. PCAT19 regulates the proliferation and apoptosis of lung cancer cells by inhibiting miR-25-3p via targeting the MAP2K4 signal axis
Song et al. miR-128 targets the CC chemokine ligand 18 gene (CCL18) in cutaneous malignant melanoma progression
Wang et al. LncRNA-NONHSAT024778 promote the proliferation and invasion of chordoma cell by regulating miR-1290/Robo1 axis
Qi et al. piR-19166 inhibits migration and metastasis through CTTN/MMPs pathway in prostate carcinoma
CN112813162B (en) Application of DDX 19A-based method for promoting cervical squamous cell carcinoma metastasis
Wu et al. ERp29 inhibits tumorigenicity by suppressing epithelial mesenchymal transition in gastric cancer
Duan et al. IGF2BPs as novel m6A readers: Diverse roles in regulating cancer cell biological functions, hypoxia adaptation, metabolism, and immunosuppressive tumor microenvironment
CN110616265B (en) Molecular marker for preventing, diagnosing and treating tongue squamous carcinoma and application thereof
CN114042161B (en) Application of CENPW inhibitor in preparation of antitumor drugs
CN107937520B (en) Molecular marker, inhibitor, kit and medicament related to colorectal cancer
CN114891795B (en) Application of long-chain non-coding RNA CRCAL-3 as breast cancer radiotherapy resistance marker

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant